Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab - 2Israeli tourist data from 2025 misrepresented as mass exodus to Thailand
- 3Investigating the Medical advantages of Aloe Vera
- 4Genome study reveals milestone in history of cat domestication
- 5Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Vote In favor of Your Favored Shades
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- Help Your Business with Master Web based Promoting Arrangements
- What to expect from the planets in 2026 — key dates and sky events
- Want to make America healthy again? Stop fueling climate change
- ONE returns to Red Sea with new service
- Oldest evidence of human fire-making discovered at site in England
- 5 Advancement Developments in Biotechnology
